GOG-0186H

Terminated

Return to Protocol Table

A Randomized Phase II Evaluation of Weekly Paclitaxel (NSC# 673089) Versus Weekly Paclitaxel with Oncolytic Reovirus (Reolysin NSC # 729968, BB-IND # 13370) in the Treatment of Recurrent or Persistent Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Principal Investigator

David Cohn

Status

Terminated

Open to Accrual

December 6, 2010

Closed to Accrual

December 6, 2010

Closed to Accrual

September 2, 2014

Closed to Accrual & Treatment

April 5, 2019

Complete

July 17, 2020

Terminated

July 17, 2020


Disease Site

Gynecologic [GY] Ovarian

Phase

II

Developmental Therapeutics

No

Primary Objective

To estimate the progression-free survival hazard ratio of the combination
of weekly paclitaxel with Reolysin® to weekly paclitaxel alone in patients
with persistent or recurrent ovarian, fallopian tube, or primary peritoneal
cancer.

To determine the frequency and severity of adverse events associated with
treatment with weekly paclitaxel alone and weekly paclitaxel with
REOLYSIN® as assessed by CTCAE.

Patient Population

Patients with persistent or recurrent ovarian, fallopian tube, or primary peritoneal
cancer.

Target Accrual

110

Patient Study Webpage

There is no available patient study webpage available for this trial at this time.